<DOC>
	<DOCNO>NCT00067470</DOCNO>
	<brief_summary>The purpose study evaluate ability rhASB versus placebo enhance endurance patient Mucopolysaccharidosis VI ( MPS VI ) , evidence increase number meter walk 12 minute walk test Week 24 compare baseline .</brief_summary>
	<brief_title>Study Recombinant Human N-acetylgalactosamine 4-sulfatase ( rhASB ) Patients With MPS VI</brief_title>
	<detailed_description />
	<mesh_term>Mucopolysaccharidoses</mesh_term>
	<mesh_term>Mucopolysaccharidosis VI</mesh_term>
	<criteria>Inclusion Criteria Patient consent Patient must seven year age old Patient must document biochemical genetic proof MPS VI The patient must able walk independently least 5 meter 270 meter first 6 minute , 400 meter total 12 minute , screen 12minute walk test If female childbearing potential , patient must negative pregnancy test Exclusion Criteria Patient consideration undergone successful bone marrow transplant ( BMT ) Patient refuse unable complete screen evaluation Pregnant lactate patient Patient receive investigational drug within 30 day prior study enrollment Patient previously treat rhASB Patient medical condition , serious intercurrent illness , extenuate circumstance may significantly confound study result decrease study compliance The patient clinically significant spinal cord compression The patient know hypersensitivity rhASB component active placebo test solution</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
</DOC>